Abstract 1361MO
Background
Addition of abiraterone acetate plus prednisone (AAP) to androgen deprivation therapy (ADT) with or without docetaxel (D), improved overall survival (OS) in men with de novo metastatic castration sensitive prostate cancer (mCSPC) in the PEACE-1 phase 3 trial (Lancet 2022; April 8). The 8-months PSA decline to undetectable levels has been associated with improved OS and radiological progression-free survival (rPFS) in mCSPC men treated with ADT plus D or AAP. We assessed the association of 8-months PSA value with rPFS and OS in mCSPC men treated in PEACE-1 with the triplet systemic association: ADT+D+AAP.
Methods
It is a preplanned analysis of data from 1172 men receiving ADT+/- D +/- AAP. The analysis required a PSA at 8 months from ADT initiation. Data cut off was 1st June 2021. rPFS and OS were assessed overall, and then by randomization groups. The analysis was performed for the following 8-month PSA cut-offs: 0.2 and 4 ng/ml. Median values of rPFS and OS were calculated from 8 months-PSA using the Kaplan Meier method.
Results
PSA values at 8 months after ADT initiation were available in 931 men (79%). Standard of care was ADT + D in 62% and 56% had “high volume” disease. The median follow-up was 4.4 years (95% CI [4.3-4.5]). Results are in the table. Table: 1361MO
Treatment | PSA < 0.2 ng/ml | PSA >0.2* ng/ml | PSA < 4 ng/ml | PSA > 4* ng/ml | |
rPFS Median (year) [CI 95%] | ADT+/- D n=439 | 4.0 [3.6-NR] | 1.4 [1.2-1.7] | 2.5 [2.0-3.1] | 0.7 [0.5-1.0] |
ADT + D n=286 | 3.7 [2.1-NR] | 1.3 [1.1-1.5] | 2.1 [1.7-3.0] | 0.5 [0.4-1.0] | |
ADT+AAP +/- D n=441 | NR [4.7-NR] | 2.2 [1.6-2.9] | 5.4 [4.1-NR] | 0.7 [0.3-1.1] | |
ADT+AAP + D n=268 | 4.7 [4.5-NR] | 2.5 [1.6-3.4] | 4.5 [3.5-NR] | 0.7 [0.3-1.2] | |
OS Median (year) [CI 95%] | ADT +/- D n=471 | NR [4.8-NR] | 3.5 [3.1-4.1] | 5.9 [4.7-NR] | 2.1 [1.7-2.4] |
ADT + D n=297 | NR [4.0-NR] | 3.5 [2.8-4.0]** | 4.5 [4.0-NR] | 2.1 [1.5-2.5] | |
ADT+AAP +/- D n=458 | NR [5.7-NR] | 3.4 [2.8-3.9] | 6.1 [5.2-NR] | 1.5 [0.9-1.9] | |
ADT+AAP + D n=276 | NR [4.7-NR] | 3.6 [2.9-NR] | NR [4.7-NR] | 1.6 [0.9-2.4] |
∗p<.0001 ∗∗0.0007 NR: Not reach, CI: confidence interval.
Conclusions
8-month PSA value strongly predicts both rPFS and OS in men with mCSPC in PEACE-1. Early therapeutic intervention in men with unfavorable 8-month PSA values needs to be investigated.
Clinical trial identification
NCT01957436.
Editorial acknowledgement
Legal entity responsible for the study
UNICANCER.
Funding
Janssen Pharmaceutical NV, Ipsen, Sanofi, French Academic Institution Financial support (PHRC).
Disclosure
G. Gravis Mescam: Financial Interests, Institutional, Advisory Board: AAA, Alliance Merck-Pfizer, Astellas, BMS, Janssen, Pfizer, ipsen, alliance Merck Pfizer; Financial Interests, Institutional, Invited Speaker: AAA, Amgen, Astellas, BMS, Janssen, MSD, Pfizer, Sanofi, Ipsen, AstraZeneca, BMS; Financial Interests, Institutional, Funding: Janssen; Non-Financial Interests, Principal Investigator: Ipsen, BMS, Merck. G. Roubaud: Financial Interests, Personal, Invited Speaker: Astellas, Ipsen, Sanofi, Janssen. R.S. McDermott: Financial Interests, Personal, Advisory Board: Pfizer, Amgen, BMS, Bayer, Janssen, Clovis; Financial Interests, Personal, Invited Speaker: MSD, Ipsen, Astellas; Financial Interests, Institutional, Invited Speaker: MSD, Clovis, BMS, Regeneron, Bayer, Astellas. A. Flechon: Financial Interests, Personal, Expert Testimony: Sanofi, AstraZeneca, Astellas, Janssen, AAA, Bayer; Financial Interests, Personal, Invited Speaker: Novartis. B. Tombal: Financial Interests, Personal, Advisory Board: Astellas, Bayer, Amgen, Janssen, Sanofi, Myovant, Novartis (AAA), Pfizer, MSD, AstraZeneca; Financial Interests, Personal, Invited Speaker: Astellas, Amgen, Ferring; Financial Interests, Personal, Expert Testimony: Astellas; Non-Financial Interests, Invited Speaker, Past President: European Organisation of Research and Treatment of Cancer (EORTC); Non-Financial Interests, Invited Speaker, Education in the field of Oncology: ISSECAM. S. Supiot: Financial Interests, Personal, Invited Speaker: Bayer, Janssen, Astellas, Ipsen, Sanofi; Financial Interests, Personal, Leadership Role: Bayer; Financial Interests, Institutional, Principal Investigator: AstraZeneca, Janssen, Astellas; Financial Interests, Personal, Project Lead: AstraZeneca, Janssen, Astellas. D.R. Berthold: Financial Interests, Institutional, Invited Speaker: Astellas, Janssen; Financial Interests, Institutional, Advisory Board: MSD, Ipsen, Bayer, BMS, Roche. G. Kacso: Financial Interests, Personal, Advisory Board: Astellas, AstraZeneca, Johnson & Johnson, Sanofi; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Officer: Amethyst; Financial Interests, Personal, Royalties: Astellas, AstraZeneca, Johnson & Johnson, Merck/ MSD, Novartis, Sanofi. F. Calabrò: Financial Interests, Personal, Advisory Board: BMS, MSD, AstraZeneca, Ipsen, Merck, Pfizer; Financial Interests, Institutional, Principal Investigator: Parexel, AstraZeneca, BMS, Syneos, MSD, PRA, IQVIA, Pfizer, J and J, Janssen, ICON, Roche, Eisai, Bayer. J.F. Berdah: Financial Interests, Personal, Invited Speaker: Janssen Cilag, Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: Astellas. A. Thiery-Vuillemin: Financial Interests, Personal, Advisory Board, & public speaking: Pfizer, astrazeneca, Janssen, Ipsen, Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: Sanofi, Novartis, Roche/Genentech, MSD, Astellas Pharma; Financial Interests, Institutional, Funding: Pfizer, Ipsen, Bayer; Financial Interests, Institutional, Invited Speaker: Pfizer, AstraZeneca, Sanofi, JNJ, Novartis, Ipsen, Roche, BMS, MSD, Astellas Pharma, Excelixis, UNICANCER / GETUG, Incyte; Financial Interests, Invited Speaker: AstraZeneca, Novartis, BMS; Non-Financial Interests, Member: ASCO, GETUG; Other, Travel, Accommodations: Roche, MSD, JNJ, BMS, AstraZeneca, Pfizer, Astellas Pharma, Ipsen. A. Rodriguez-Vida: Financial Interests, Personal, Invited Speaker: Roche, MSD, Pfizer, BMS, Astellas, Janssen, Bayer, Clovis, AstraZeneca, Sanofi; Financial Interests, Personal, Principal Investigator: Takeda, Pfizer, Merck. K. Fizazi: Financial Interests, Institutional, Advisory Board: Astellas, Bayer, Janssen, AAA, MSD, AstraZeneca, Novartis/AAA, Pfizer; Financial Interests, Institutional, Invited Speaker: Astellas, Bayer, Janssen, Sanofi, MSD, AstraZeneca, Novartis, Pfizer; Financial Interests, Personal, Advisory Board: Curevac, Orion; Financial Interests, Institutional, Research Grant, Trial chair: Pfizer, Bayer, AstraZeneca, Orion, MSD, BMS, Janssen; Non-Financial Interests, Principal Investigator, Chair of the 7DX phase 3 trial: BMS; Non-Financial Interests, Principal Investigator, Chair of the Docetaxel-pembrolizumab phase 3 trial: Merck; Non-Financial Interests, Principal Investigator, Chair of the Darolutamide BCR phase 3 trial: Bayer; Non-Financial Interests, Principal Investigator, Chair of the PSMAfore phase 3 trial: AAA/Novartis; Non-Financial Interests, Principal Investigator, Chair of the CYPIDES ODM-208 Phase I-II trial: Orion; Non-Financial Interests, Principal Investigator, Chair of the STESIDES ODM-209 Phase I-II trial: Orion. All other authors have declared no conflicts of interest.
Resources from the same session
1360MO - Quality of life and patient-relevant endpoints with darolutamide in the phase III ARASENS study
Presenter: Karim Fizazi
Session: Mini Oral session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
LBA64 - Duration of androgen suppression with post-operative radiotherapy (DADSPORT): A collaborative meta-analysis of aggregate data
Presenter: Sarah Burdett
Session: Mini Oral session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant 1360MO and LBA64
Presenter: Nicolas Mottet
Session: Mini Oral session: GU tumours, prostate
Resources:
Slides
Webcast
1359MO - Differential treatment response with nodal metastases in metastatic hormone-sensitive prostate cancer (mHSPC) and evaluation of nodal (N) burden as a prognostic biomarker: Ancillary studies of the docetaxel and abiraterone acetate and prednisolone (AAP) phase III trials from STAMPEDE
Presenter: Áine Haran
Session: Mini Oral session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant 1359MO and 1361MO
Presenter: Boris Hadaschik
Session: Mini Oral session: GU tumours, prostate
Resources:
Slides
Webcast
LBA65 - SAKK 08/14 - IMPROVE Investigation of metformin in patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with enzalutamide vs. enzalutamide alone. A randomized, open label, phase II trial
Presenter: Christian Rothermundt
Session: Mini Oral session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
1362MO - Pembrolizumab + olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study
Presenter: Evan Yu
Session: Mini Oral session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
1363MO - Cabazitaxel every 2 weeks versus every 3 weeks in older patients with metastatic castration-resistant prostate cancer (mCRPC): The CABASTY randomized phase III trial
Presenter: Stephane Oudard
Session: Mini Oral session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
1364MO - Preliminary phase II results of the CYPIDES study of ODM-208 in metastatic castration-resistant prostate (mCRPC) cancer patients
Presenter: Karim Fizazi
Session: Mini Oral session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA65, 1362MO, 1363MO and 1364MO
Presenter: Martijn Lolkema
Session: Mini Oral session: GU tumours, prostate
Resources:
Slides
Webcast